Loading clinical trials...
Loading clinical trials...
A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Conditions
Interventions
Lenti-D Drug Product (eli-cel)
Locations
8
United States
Mattel Children's Hospital UCLA/Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Boston Children's Hospital/Massachusetts General Hospital
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Medeos SRL
Buenos Aires, Argentina
Women and Children's Hospital
North Adelaide, South Australia, Australia
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Start Date
August 21, 2013
Primary Completion Date
March 26, 2021
Completion Date
March 26, 2021
Last Updated
April 25, 2022
NCT05819866
NCT02698579
Lead Sponsor
Genetix Biotherapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions